ArticleNature communications2022

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.

John Hilton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.